Please assess the completion status of the following clinical trial:

Trial Title: Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older.~* Diagnosed by preoperative imaging modalities to have a brain tumor or vascular lesions (aneurysm, arteriovenous malformation or arteriovenous fistula) requiring surgical intervention.~* The patient is determined by a board certified Neurosurgeon (above mentioned neurosurgeons) to benefit from the application of Fluorescein Sodium intraoperatively~* Patient or legally authorized representative provides written informed consent to enroll in this study.~Exclusion Criteria:~* Known allergic reaction to Fluorescein Sodium.~* Children.~* Prisoners.~* Students.~* Infection of the central nervous system or other sites.~* Hemodynamic instability or significant impairments in circulation.~* Concomitant treatment with other investigational drugs.~* Any uncontrolled condition unrelated to the neurosurgical disease.~* History of psychiatric, additive, or any other disorder that compromises the ability to provide informed consent or comply with study protocols.~* Participation on other clinical trials during the last thirty days.~* Pregnant patients.~* Patients unable to discontinue medications that affect Fluorescein metabolism.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluorescein Sodium (Type: EXPERIMENTAL): All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.

Based on this trial design, predict the completion outcome and termination type (if applicable).